GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sihuan Pharmaceutical Holdings Group Ltd (OTCPK:SHPHF) » Definitions » Beginning Cash Position

Sihuan Pharmaceutical Holdings Group (Sihuan Pharmaceutical Holdings Group) Beginning Cash Position : $523.0 Mil (As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Sihuan Pharmaceutical Holdings Group Beginning Cash Position?

Sihuan Pharmaceutical Holdings Group's Beginning Cash Position for the quarter that ended in Dec. 2023 was $523.0 Mil.

Sihuan Pharmaceutical Holdings Group's quarterly Beginning Cash Position declined from Dec. 2022 ($730.9 Mil) to Jun. 2023 ($534.7 Mil) and declined from Jun. 2023 ($534.7 Mil) to Dec. 2023 ($523.0 Mil).

Sihuan Pharmaceutical Holdings Group's annual Beginning Cash Position increased from Dec. 2021 ($722.8 Mil) to Dec. 2022 ($815.1 Mil) but then declined from Dec. 2022 ($815.1 Mil) to Dec. 2023 ($536.2 Mil).

Sihuan Pharmaceutical Holdings Group Beginning Cash Position Historical Data

The historical data trend for Sihuan Pharmaceutical Holdings Group's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sihuan Pharmaceutical Holdings Group Beginning Cash Position Chart

Sihuan Pharmaceutical Holdings Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 472.63 782.52 722.85 815.07 536.24

Sihuan Pharmaceutical Holdings Group Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 727.06 848.73 730.90 534.65 522.96

Sihuan Pharmaceutical Holdings Group Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Sihuan Pharmaceutical Holdings Group Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Sihuan Pharmaceutical Holdings Group's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Sihuan Pharmaceutical Holdings Group (Sihuan Pharmaceutical Holdings Group) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sihuan Pharmaceutical Holdings Group Ltd (OTCPK:SHPHF) » Definitions » Beginning Cash Position
Comparable Companies
HKSE:01681 HKSE:01349 HKSE:02877 HKSE:06896 HKSE:03613 HKSE:06185 HKSE:02348 HKSE:02552 HKSE:01061 HKSE:02633 ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA XSWX:SDZ VTRS SZSE:000538 NBIX
Traded in Other Exchanges
00460:Hong Kong
Address
Zhubang 2000 Business Centre, 22nd Floor, Building 4, West Balizhuang, Chaoyang District, Beijing, CHN, 100025
Website
https://www.sihuanpharm.com
Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company. Along with its subsidiaries, the company is engaged in the research & development and the manufacture & sale of pharmaceutical products. Its portfolio comprises products for diseases related to the cardio-cerebral vascular (CCV) system, Digestive System, Anti-Infective, metabolism, Respiratory, Neurology, and Others. The group has three reportable segments: the medical aesthetic products segment including the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skincare, and others to provide non- or minimally invasive medical aesthetics comprehensive solutions; the innovative medicine and other medicine segments; and the generic medicine segment.